 | • レポートコード：GIR201109951 • 出版社/出版日：GlobalInfoResearch / 2020年10月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、153ページ • 納品方法：Eメール • 産業分類：医薬品・医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本書では、腫瘍壊死因子阻害薬の世界市場を調査対象にし、腫瘍壊死因子阻害薬の市場概要、メーカー情報、メーカー別販売量・売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（シムジア（セルトリズマブペゴル）、エンブレル（エタネルセプト）、ヒュミラ(アダリムマブ)、オズテラ（アプレミラスト）、レミケード（インフリキシマブ）、シンポニー（ゴリムマブ））、用途別分析（病院、診療所、その他）、市場予測（2021年～2025年）、販売チャンネル・代理店分析情報などを整理しました。 ・市場概要 ・メーカー情報：Apogenix、Dexa Medica、CASI Pharmaceuticals、AryoGen Biopharma、Delenex Therapeutics、Bionovis、Janssen Biotech、Celgene Corporation、Celltrion、EPIRUS Biopharmaceuticals、LG Life Sciences、Novartis、GlaxoSmithKline、Reliance Life Sciences、MedImmune、LEO Pharma、HanAll Biopharma、PROBIOMED、Momenta Pharmaceuticals、Intas Pharmaceuticals、Toyama Chemical、Sandoz、Simcere Pharmaceutical、Shanghai Pharmaceuticals、UCB、Shanghai CP Guojian Pharmaceutical、Zydus Cadila、Samsung Bioepis、Tsumura、Sanofi-Aventis ・メーカー別販売量、売上、市場シェア ・腫瘍壊死因子阻害薬の地域別市場分析 ・腫瘍壊死因子阻害薬の北米市場規模2015-2020：アメリカ、カナダ、メキシコ ・腫瘍壊死因子阻害薬のヨーロッパ市場規模2015-2020：ドイツ、イギリス、フランス、ロシアなど ・腫瘍壊死因子阻害薬のアジア市場規模2015-2020：日本、中国、韓国、インド、東南アジアなど ・腫瘍壊死因子阻害薬の南米市場規模2015-2020：ブラジル、アルゼンチンなど ・腫瘍壊死因子阻害薬の中東・アフリカ市場規模2015-2020：サウジアラビア、トルコ、エジプト、南アフリカなど ・腫瘍壊死因子阻害薬の種類別市場規模2015-2020：シムジア（セルトリズマブペゴル）、エンブレル（エタネルセプト）、ヒュミラ(アダリムマブ)、オズテラ（アプレミラスト）、レミケード（インフリキシマブ）、シンポニー（ゴリムマブ） ・腫瘍壊死因子阻害薬の用途別市場規模2015-2020：病院、診療所、その他 ・腫瘍壊死因子阻害薬の世界市場予測2021-2025：地域別、種類別、用途別 ・販売チャンネル・代理店分析 ・調査の結果・結論 |
Market Overview
The global Tumor Necrosis Factor Inhibitors Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Tumor Necrosis Factor Inhibitors Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Tumor Necrosis Factor Inhibitors Drug market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Tumor Necrosis Factor Inhibitors Drug market has been segmented into
Cimzia (Certolizumab Pegol)
Enbrel (Etanercept)
Humira ( Adalimumab)
Otezla (Apremilast)
Remicade (Infliximab)
Simponi (Golimumab)
By Application, Tumor Necrosis Factor Inhibitors Drug has been segmented into:
Clinic
Hospital
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Tumor Necrosis Factor Inhibitors Drug market presented in the report. This section sheds light on the sales growth of different regional and country-level Tumor Necrosis Factor Inhibitors Drug markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Tumor Necrosis Factor Inhibitors Drug market.
The report offers in-depth assessment of the growth and other aspects of the Tumor Necrosis Factor Inhibitors Drug market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Tumor Necrosis Factor Inhibitors Drug Market Share Analysis
Tumor Necrosis Factor Inhibitors Drug competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Tumor Necrosis Factor Inhibitors Drug sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Tumor Necrosis Factor Inhibitors Drug sales, revenue and market share for each player covered in this report.
The major players covered in Tumor Necrosis Factor Inhibitors Drug are:
Apogenix
Dexa Medica
CASI Pharmaceuticals
AryoGen Biopharma
Delenex Therapeutics
Bionovis
Janssen Biotech
Celgene Corporation
Celltrion
EPIRUS Biopharmaceuticals
LG Life Sciences
Novartis
GlaxoSmithKline
Reliance Life Sciences
MedImmune
LEO Pharma
HanAll Biopharma
PROBIOMED
Momenta Pharmaceuticals
Intas Pharmaceuticals
Toyama Chemical
Sandoz
Simcere Pharmaceutical
Shanghai Pharmaceuticals
UCB
Shanghai CP Guojian Pharmaceutical
Zydus Cadila
Samsung Bioepis
Tsumura
Sanofi-Aventis
Among other players domestic and global, Tumor Necrosis Factor Inhibitors Drug market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Tumor Necrosis Factor Inhibitors Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Tumor Necrosis Factor Inhibitors Drug, with price, sales, revenue and global market share of Tumor Necrosis Factor Inhibitors Drug in 2018 and 2019.
Chapter 3, the Tumor Necrosis Factor Inhibitors Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Tumor Necrosis Factor Inhibitors Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Tumor Necrosis Factor Inhibitors Drug market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Tumor Necrosis Factor Inhibitors Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Tumor Necrosis Factor Inhibitors Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Tumor Necrosis Factor Inhibitors Drug Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Cimzia (Certolizumab Pegol)
1.2.3 Enbrel (Etanercept)
1.2.4 Humira ( Adalimumab)
1.2.5 Otezla (Apremilast)
1.2.6 Remicade (Infliximab)
1.2.7 Simponi (Golimumab)
1.3 Market Analysis by Application
1.3.1 Overview: Global Tumor Necrosis Factor Inhibitors Drug Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Overview of Global Tumor Necrosis Factor Inhibitors Drug Market
1.4.1 Global Tumor Necrosis Factor Inhibitors Drug Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Apogenix
2.1.1 Apogenix Details
2.1.2 Apogenix Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Apogenix SWOT Analysis
2.1.4 Apogenix Product and Services
2.1.5 Apogenix Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Dexa Medica
2.2.1 Dexa Medica Details
2.2.2 Dexa Medica Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Dexa Medica SWOT Analysis
2.2.4 Dexa Medica Product and Services
2.2.5 Dexa Medica Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 CASI Pharmaceuticals
2.3.1 CASI Pharmaceuticals Details
2.3.2 CASI Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 CASI Pharmaceuticals SWOT Analysis
2.3.4 CASI Pharmaceuticals Product and Services
2.3.5 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 AryoGen Biopharma
2.4.1 AryoGen Biopharma Details
2.4.2 AryoGen Biopharma Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 AryoGen Biopharma SWOT Analysis
2.4.4 AryoGen Biopharma Product and Services
2.4.5 AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Delenex Therapeutics
2.5.1 Delenex Therapeutics Details
2.5.2 Delenex Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Delenex Therapeutics SWOT Analysis
2.5.4 Delenex Therapeutics Product and Services
2.5.5 Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Bionovis
2.6.1 Bionovis Details
2.6.2 Bionovis Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Bionovis SWOT Analysis
2.6.4 Bionovis Product and Services
2.6.5 Bionovis Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Janssen Biotech
2.7.1 Janssen Biotech Details
2.7.2 Janssen Biotech Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Janssen Biotech SWOT Analysis
2.7.4 Janssen Biotech Product and Services
2.7.5 Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Celgene Corporation
2.8.1 Celgene Corporation Details
2.8.2 Celgene Corporation Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Celgene Corporation SWOT Analysis
2.8.4 Celgene Corporation Product and Services
2.8.5 Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 Celltrion
2.9.1 Celltrion Details
2.9.2 Celltrion Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Celltrion SWOT Analysis
2.9.4 Celltrion Product and Services
2.9.5 Celltrion Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 EPIRUS Biopharmaceuticals
2.10.1 EPIRUS Biopharmaceuticals Details
2.10.2 EPIRUS Biopharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 EPIRUS Biopharmaceuticals SWOT Analysis
2.10.4 EPIRUS Biopharmaceuticals Product and Services
2.10.5 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.11 LG Life Sciences
2.11.1 LG Life Sciences Details
2.11.2 LG Life Sciences Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 LG Life Sciences SWOT Analysis
2.11.4 LG Life Sciences Product and Services
2.11.5 LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.12 Novartis
2.12.1 Novartis Details
2.12.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Novartis SWOT Analysis
2.12.4 Novartis Product and Services
2.12.5 Novartis Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.13 GlaxoSmithKline
2.13.1 GlaxoSmithKline Details
2.13.2 GlaxoSmithKline Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 GlaxoSmithKline SWOT Analysis
2.13.4 GlaxoSmithKline Product and Services
2.13.5 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.14 Reliance Life Sciences
2.14.1 Reliance Life Sciences Details
2.14.2 Reliance Life Sciences Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Reliance Life Sciences SWOT Analysis
2.14.4 Reliance Life Sciences Product and Services
2.14.5 Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.15 MedImmune
2.15.1 MedImmune Details
2.15.2 MedImmune Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 MedImmune SWOT Analysis
2.15.4 MedImmune Product and Services
2.15.5 MedImmune Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.16 LEO Pharma
2.16.1 LEO Pharma Details
2.16.2 LEO Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 LEO Pharma SWOT Analysis
2.16.4 LEO Pharma Product and Services
2.16.5 LEO Pharma Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.17 HanAll Biopharma
2.17.1 HanAll Biopharma Details
2.17.2 HanAll Biopharma Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 HanAll Biopharma SWOT Analysis
2.17.4 HanAll Biopharma Product and Services
2.17.5 HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.18 PROBIOMED
2.18.1 PROBIOMED Details
2.18.2 PROBIOMED Major Business and Total Revenue (Financial Highlights) Analysis
2.18.3 PROBIOMED SWOT Analysis
2.18.4 PROBIOMED Product and Services
2.18.5 PROBIOMED Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.19 Momenta Pharmaceuticals
2.19.1 Momenta Pharmaceuticals Details
2.19.2 Momenta Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.19.3 Momenta Pharmaceuticals SWOT Analysis
2.19.4 Momenta Pharmaceuticals Product and Services
2.19.5 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.20 Intas Pharmaceuticals
2.20.1 Intas Pharmaceuticals Details
2.20.2 Intas Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.20.3 Intas Pharmaceuticals SWOT Analysis
2.20.4 Intas Pharmaceuticals Product and Services
2.20.5 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.21 Toyama Chemical
2.21.1 Toyama Chemical Details
2.21.2 Toyama Chemical Major Business and Total Revenue (Financial Highlights) Analysis
2.21.3 Toyama Chemical SWOT Analysis
2.21.4 Toyama Chemical Product and Services
2.21.5 Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.22 Sandoz
2.22.1 Sandoz Details
2.22.2 Sandoz Major Business and Total Revenue (Financial Highlights) Analysis
2.22.3 Sandoz SWOT Analysis
2.22.4 Sandoz Product and Services
2.22.5 Sandoz Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.23 Simcere Pharmaceutical
2.23.1 Simcere Pharmaceutical Details
2.23.2 Simcere Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.23.3 Simcere Pharmaceutical SWOT Analysis
2.23.4 Simcere Pharmaceutical Product and Services
2.23.5 Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.24 Shanghai Pharmaceuticals
2.24.1 Shanghai Pharmaceuticals Details
2.24.2 Shanghai Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.24.3 Shanghai Pharmaceuticals SWOT Analysis
2.24.4 Shanghai Pharmaceuticals Product and Services
2.24.5 Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.25 UCB
2.25.1 UCB Details
2.25.2 UCB Major Business and Total Revenue (Financial Highlights) Analysis
2.25.3 UCB SWOT Analysis
2.25.4 UCB Product and Services
2.25.5 UCB Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.26 Shanghai CP Guojian Pharmaceutical
2.26.1 Shanghai CP Guojian Pharmaceutical Details
2.26.2 Shanghai CP Guojian Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.26.3 Shanghai CP Guojian Pharmaceutical SWOT Analysis
2.26.4 Shanghai CP Guojian Pharmaceutical Product and Services
2.26.5 Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.27 Zydus Cadila
2.27.1 Zydus Cadila Details
2.27.2 Zydus Cadila Major Business and Total Revenue (Financial Highlights) Analysis
2.27.3 Zydus Cadila SWOT Analysis
2.27.4 Zydus Cadila Product and Services
2.27.5 Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.28 Samsung Bioepis
2.28.1 Samsung Bioepis Details
2.28.2 Samsung Bioepis Major Business and Total Revenue (Financial Highlights) Analysis
2.28.3 Samsung Bioepis SWOT Analysis
2.28.4 Samsung Bioepis Product and Services
2.28.5 Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.29 Tsumura
2.29.1 Tsumura Details
2.29.2 Tsumura Major Business and Total Revenue (Financial Highlights) Analysis
2.29.3 Tsumura SWOT Analysis
2.29.4 Tsumura Product and Services
2.29.5 Tsumura Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.30 Sanofi-Aventis
2.30.1 Sanofi-Aventis Details
2.30.2 Sanofi-Aventis Major Business and Total Revenue (Financial Highlights) Analysis
2.30.3 Sanofi-Aventis SWOT Analysis
2.30.4 Sanofi-Aventis Product and Services
2.30.5 Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Tumor Necrosis Factor Inhibitors Drug Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Tumor Necrosis Factor Inhibitors Drug Manufacturer Market Share in 2019
3.3.2 Top 6 Tumor Necrosis Factor Inhibitors Drug Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Market Share by Regions
4.1.1 Global Tumor Necrosis Factor Inhibitors Drug Sales and Market Share by Regions (2015-2020)
4.1.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue and Market Share by Regions (2015-2020)
4.2 North America Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
4.3 Europe Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
4.5 South America Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Market Share by Country
5.1.1 North America Tumor Necrosis Factor Inhibitors Drug Sales and Market Share by Country (2015-2020)
5.1.2 North America Tumor Necrosis Factor Inhibitors Drug Revenue and Market Share by Country (2015-2020)
5.2 United States Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
5.3 Canada Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
5.4 Mexico Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Market Share by Country
6.1.1 Europe Tumor Necrosis Factor Inhibitors Drug Sales and Market Share by Country (2015-2020)
6.1.2 Europe Tumor Necrosis Factor Inhibitors Drug Revenue and Market Share by Country (2015-2020)
6.2 Germany Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
6.3 UK Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
6.4 France Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
6.5 Russia Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
6.6 Italy Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Revenue and Market Share by Regions (2015-2020)
7.2 China Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
7.3 Japan Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
7.4 Korea Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
7.5 India Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
7.7 Australia Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Market Share by Country
8.1.1 South America Tumor Necrosis Factor Inhibitors Drug Sales and Market Share by Country (2015-2020)
8.1.2 South America Tumor Necrosis Factor Inhibitors Drug Revenue and Market Share by Country (2015-2020)
8.2 Brazil Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
8.3 Argentina Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
9.3 Turkey Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
9.4 Egypt Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
9.5 South Africa Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Tumor Necrosis Factor Inhibitors Drug Sales and Market Share by Type (2015-2020)
10.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue and Market Share by Type (2015-2020)
10.3 Global Tumor Necrosis Factor Inhibitors Drug Price by Type (2015-2020)
11 Global Tumor Necrosis Factor Inhibitors Drug Market Segment by Application
11.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2015-2020)
11.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Application (2015-2020)
11.3 Global Tumor Necrosis Factor Inhibitors Drug Price by Application (2015-2020)
12 Market Forecast
12.1 Global Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Growth Rate (2021-2025)
12.2 Tumor Necrosis Factor Inhibitors Drug Market Forecast by Regions (2021-2025)
12.2.1 North America Tumor Necrosis Factor Inhibitors Drug Market Forecast (2021-2025)
12.2.2 Europe Tumor Necrosis Factor Inhibitors Drug Market Forecast (2021-2025)
12.2.3 Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Market Forecast (2021-2025)
12.2.4 South America Tumor Necrosis Factor Inhibitors Drug Market Forecast (2021-2025)
12.2.5 Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Market Forecast (2021-2025)
12.3 Tumor Necrosis Factor Inhibitors Drug Market Forecast by Type (2021-2025)
12.3.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Type (2021-2025)
12.3.2 Global Tumor Necrosis Factor Inhibitors Drug Market Share Forecast by Type (2021-2025)
12.4 Tumor Necrosis Factor Inhibitors Drug Market Forecast by Application (2021-2025)
12.4.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Application (2021-2025)
12.4.2 Global Tumor Necrosis Factor Inhibitors Drug Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Tumor Necrosis Factor Inhibitors Drug Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Tumor Necrosis Factor Inhibitors Drug by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Tumor Necrosis Factor Inhibitors Drug Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Apogenix Basic Information, Manufacturing Base and Competitors
Table 8. Apogenix Tumor Necrosis Factor Inhibitors Drug Major Business
Table 9. Apogenix Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 10. Apogenix SWOT Analysis
Table 11. Apogenix Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 12. Apogenix Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Dexa Medica Basic Information, Manufacturing Base and Competitors
Table 14. Dexa Medica Tumor Necrosis Factor Inhibitors Drug Major Business
Table 15. Dexa Medica Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 16. Dexa Medica SWOT Analysis
Table 17. Dexa Medica Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 18. Dexa Medica Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. CASI Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 20. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Major Business
Table 21. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 22. CASI Pharmaceuticals SWOT Analysis
Table 23. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 24. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. AryoGen Biopharma Basic Information, Manufacturing Base and Competitors
Table 26. AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Major Business
Table 27. AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 28. AryoGen Biopharma SWOT Analysis
Table 29. AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 30. AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. Delenex Therapeutics Basic Information, Manufacturing Base and Competitors
Table 32. Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Major Business
Table 33. Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 34. Delenex Therapeutics SWOT Analysis
Table 35. Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 36. Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Bionovis Basic Information, Manufacturing Base and Competitors
Table 38. Bionovis Tumor Necrosis Factor Inhibitors Drug Major Business
Table 39. Bionovis Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 40. Bionovis SWOT Analysis
Table 41. Bionovis Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 42. Bionovis Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Janssen Biotech Basic Information, Manufacturing Base and Competitors
Table 44. Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Major Business
Table 45. Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 46. Janssen Biotech SWOT Analysis
Table 47. Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 48. Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. Celgene Corporation Basic Information, Manufacturing Base and Competitors
Table 50. Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Major Business
Table 51. Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 52. Celgene Corporation SWOT Analysis
Table 53. Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 54. Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. Celltrion Basic Information, Manufacturing Base and Competitors
Table 56. Celltrion Tumor Necrosis Factor Inhibitors Drug Major Business
Table 57. Celltrion Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 58. Celltrion SWOT Analysis
Table 59. Celltrion Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 60. Celltrion Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 61. EPIRUS Biopharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 62. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Major Business
Table 63. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 64. EPIRUS Biopharmaceuticals SWOT Analysis
Table 65. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 66. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 67. LG Life Sciences Basic Information, Manufacturing Base and Competitors
Table 68. LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Major Business
Table 69. LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 70. LG Life Sciences SWOT Analysis
Table 71. LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 72. LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 73. Novartis Basic Information, Manufacturing Base and Competitors
Table 74. Novartis Tumor Necrosis Factor Inhibitors Drug Major Business
Table 75. Novartis Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 76. Novartis SWOT Analysis
Table 77. Novartis Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 78. Novartis Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 79. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 80. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Major Business
Table 81. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 82. GlaxoSmithKline SWOT Analysis
Table 83. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 84. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 85. Reliance Life Sciences Basic Information, Manufacturing Base and Competitors
Table 86. Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Major Business
Table 87. Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 88. Reliance Life Sciences SWOT Analysis
Table 89. Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 90. Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 91. MedImmune Basic Information, Manufacturing Base and Competitors
Table 92. MedImmune Tumor Necrosis Factor Inhibitors Drug Major Business
Table 93. MedImmune Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 94. MedImmune SWOT Analysis
Table 95. MedImmune Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 96. MedImmune Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 97. LEO Pharma Basic Information, Manufacturing Base and Competitors
Table 98. LEO Pharma Tumor Necrosis Factor Inhibitors Drug Major Business
Table 99. LEO Pharma Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 100. LEO Pharma SWOT Analysis
Table 101. LEO Pharma Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 102. LEO Pharma Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 103. HanAll Biopharma Basic Information, Manufacturing Base and Competitors
Table 104. HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Major Business
Table 105. HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 106. HanAll Biopharma SWOT Analysis
Table 107. HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 108. HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 109. PROBIOMED Tumor Necrosis Factor Inhibitors Drug Type and Application
Table 110. PROBIOMED Tumor Necrosis Factor Inhibitors Drug Major Business
Table 111. PROBIOMED Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 112. PROBIOMED SWOT Analysis
Table 113. PROBIOMED Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 114. PROBIOMED Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 115. Momenta Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 116. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Major Business
Table 117. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 118. Momenta Pharmaceuticals SWOT Analysis
Table 119. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 120. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 121. Intas Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 122. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Major Business
Table 123. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 124. Intas Pharmaceuticals SWOT Analysis
Table 125. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 126. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 127. Toyama Chemical Basic Information, Manufacturing Base and Competitors
Table 128. Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Major Business
Table 129. Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 130. Toyama Chemical SWOT Analysis
Table 131. Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 132. Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 133. Sandoz Basic Information, Manufacturing Base and Competitors
Table 134. Sandoz Tumor Necrosis Factor Inhibitors Drug Major Business
Table 135. Sandoz Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 136. Sandoz SWOT Analysis
Table 137. Sandoz Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 138. Sandoz Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 139. Simcere Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 140. Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Major Business
Table 141. Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 142. Simcere Pharmaceutical SWOT Analysis
Table 143. Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 144. Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 145. Shanghai Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 146. Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Major Business
Table 147. Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 148. Shanghai Pharmaceuticals SWOT Analysis
Table 149. Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 150. Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 151. UCB Basic Information, Manufacturing Base and Competitors
Table 152. UCB Tumor Necrosis Factor Inhibitors Drug Major Business
Table 153. UCB Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 154. UCB SWOT Analysis
Table 155. UCB Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 156. UCB Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 157. Shanghai CP Guojian Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 158. Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Major Business
Table 159. Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 160. Shanghai CP Guojian Pharmaceutical SWOT Analysis
Table 161. Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 162. Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 163. Zydus Cadila Basic Information, Manufacturing Base and Competitors
Table 164. Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Major Business
Table 165. Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 166. Zydus Cadila SWOT Analysis
Table 167. Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 168. Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 169. Samsung Bioepis Basic Information, Manufacturing Base and Competitors
Table 170. Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Major Business
Table 171. Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 172. Samsung Bioepis SWOT Analysis
Table 173. Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 174. Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 175. Tsumura Basic Information, Manufacturing Base and Competitors
Table 176. Tsumura Tumor Necrosis Factor Inhibitors Drug Major Business
Table 177. Tsumura Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 178. Tsumura SWOT Analysis
Table 179. Tsumura Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 180. Tsumura Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 181. Sanofi-Aventis Basic Information, Manufacturing Base and Competitors
Table 182. Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Major Business
Table 183. Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Total Revenue (USD Million) (2018-2019)
Table 184. Sanofi-Aventis SWOT Analysis
Table 185. Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Product and Services
Table 186. Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 187. Global Tumor Necrosis Factor Inhibitors Drug Sales by Manufacturer (2018-2019) (K Pcs)
Table 188. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Manufacturer (2018-2019) (USD Million)
Table 189. Global Tumor Necrosis Factor Inhibitors Drug Sales by Regions (2015-2020) (K Pcs)
Table 190. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Regions (2015-2020)
Table 191. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Regions (2015-2020) (USD Million)
Table 192. North America Tumor Necrosis Factor Inhibitors Drug Sales by Countries (2015-2020) (K Pcs)
Table 193. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Countries (2015-2020)
Table 194. North America Tumor Necrosis Factor Inhibitors Drug Revenue by Countries (2015-2020) (USD Million)
Table 195. North America Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Countries (2015-2020)
Table 196. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Countries (2015-2020) (K Pcs)
Table 197. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Countries (2015-2020)
Table 198. Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Countries (2015-2020) (USD Million)
Table 199. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales by Regions (2015-2020) (K Pcs)
Table 200. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Regions (2015-2020)
Table 201. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Revenue by Regions (2015-2020) (USD Million)
Table 202. South America Tumor Necrosis Factor Inhibitors Drug Sales by Countries (2015-2020) (K Pcs)
Table 203. South America Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Countries (2015-2020)
Table 204. South America Tumor Necrosis Factor Inhibitors Drug Revenue by Countries (2015-2020) (USD Million)
Table 205. South America Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Countries (2015-2020)
Table 206. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales by Countries (2015-2020) (K Pcs)
Table 207. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Countries (2015-2020)
Table 208. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Revenue by Countries (2015-2020) (USD Million)
Table 209. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Countries (2015-2020)
Table 210. Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2015-2020) (K Pcs)
Table 211. Global Tumor Necrosis Factor Inhibitors Drug Sales Share by Type (2015-2020)
Table 212. Global Tumor Necrosis Factor Inhibitors Drug Revenue by Type (2015-2020) (USD Million)
Table 213. Global Tumor Necrosis Factor Inhibitors Drug Revenue Share by Type (2015-2020)
Table 214. Global Tumor Necrosis Factor Inhibitors Drug Sales by Application (2015-2020) (K Pcs)
Table 215. Global Tumor Necrosis Factor Inhibitors Drug Sales Share by Application (2015-2020)
Table 216. Global Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Regions (2021-2025) (K Pcs)
Table 217. Global Tumor Necrosis Factor Inhibitors Drug Market Share Forecast by Regions (2021-2025)
Table 218. Global Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Type (2021-2025) (K Pcs)
Table 219. Global Tumor Necrosis Factor Inhibitors Drug Market Share Forecast by Type (2021-2025)
Table 220. Global Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Application (2021-2025)
Table 221. Global Tumor Necrosis Factor Inhibitors Drug Market Share Forecast by Application (2021-2025)
Table 222. Direct Channel Pros & Cons
Table 223. Indirect Channel Pros & Cons
Table 224. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Tumor Necrosis Factor Inhibitors Drug Picture
Figure 2. Global Sales Market Share of Tumor Necrosis Factor Inhibitors Drug by Type in 2019
Figure 3. Cimzia (Certolizumab Pegol) Picture
Figure 4. Enbrel (Etanercept) Picture
Figure 5. Humira ( Adalimumab) Picture
Figure 6. Otezla (Apremilast) Picture
Figure 7. Remicade (Infliximab) Picture
Figure 8. Simponi (Golimumab) Picture
Figure 9. Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application in 2018
Figure 10. Clinic Picture
Figure 11. Hospital Picture
Figure 12. Others Picture
Figure 13. Global Tumor Necrosis Factor Inhibitors Drug Market Status and Outlook (2015-2025) (USD Million)
Figure 14. United States Tumor Necrosis Factor Inhibitors Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 15. Canada Tumor Necrosis Factor Inhibitors Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Mexico Tumor Necrosis Factor Inhibitors Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Germany Tumor Necrosis Factor Inhibitors Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 18. France Tumor Necrosis Factor Inhibitors Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 19. UK Tumor Necrosis Factor Inhibitors Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Russia Tumor Necrosis Factor Inhibitors Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Italy Tumor Necrosis Factor Inhibitors Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 22. China Tumor Necrosis Factor Inhibitors Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Japan Tumor Necrosis Factor Inhibitors Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Korea Tumor Necrosis Factor Inhibitors Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 25. India Tumor Necrosis Factor Inhibitors Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Southeast Asia Tumor Necrosis Factor Inhibitors Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Australia Tumor Necrosis Factor Inhibitors Drug Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 28. Brazil Tumor Necrosis Factor Inhibitors Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Egypt Tumor Necrosis Factor Inhibitors Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Saudi Arabia Tumor Necrosis Factor Inhibitors Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 31. South Africa Tumor Necrosis Factor Inhibitors Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 32. Turkey Tumor Necrosis Factor Inhibitors Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 33. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Manufacturer in 2019
Figure 34. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Manufacturer in 2019
Figure 35. Top 3 Tumor Necrosis Factor Inhibitors Drug Manufacturer (Revenue) Market Share in 2019
Figure 36. Top 6 Tumor Necrosis Factor Inhibitors Drug Manufacturer (Revenue) Market Share in 2019
Figure 37. Key Manufacturer Market Share Trend
Figure 38. Global Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 39. Global Tumor Necrosis Factor Inhibitors Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 40. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Regions (2015-2020)
Figure 41. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Regions in 2018
Figure 42. North America Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
Figure 43. Europe Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
Figure 44. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
Figure 45. South America Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
Figure 46. Middle East & Africa Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020)
Figure 47. North America Tumor Necrosis Factor Inhibitors Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 48. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Countries (2015-2020)
Figure 49. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Countries in 2018
Figure 50. North America Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 51. North America Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Countries in 2018
Figure 52. United States Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 53. Canada Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 54. Mexico Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 55. Europe Tumor Necrosis Factor Inhibitors Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 56. Europe Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Countries (2015-2020)
Figure 57. Europe Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Countries in 2019
Figure 58. Germany Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 59. UK Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 60. France Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 61. Russia Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 62. Italy Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 63. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 64. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Regions 2019
Figure 65. Asia-Pacific Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Regions 2019
Figure 66. China Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 67. Japan Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 68. Korea Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 69. India Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 70. Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 71. South America Tumor Necrosis Factor Inhibitors Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 72. South America Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Countries in 2019
Figure 73. South America Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Countries in 2019
Figure 74. Brazil Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 75. Argentina Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 76. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 77. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Countries in 2019
Figure 78. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Countries (2015-2020)
Figure 79. Middle East and Africa Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Countries in 2019
Figure 80. Saudi Arabia Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 81. Egypt Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 82. Turkey Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 83. South Africa Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2015-2020) (K Pcs)
Figure 84. Global Tumor Necrosis Factor Inhibitors Drug Sales and Growth Rate (2021-2025) (K Pcs)
Figure 85. Global Tumor Necrosis Factor Inhibitors Drug Revenue and Growth Rate (2021-2025) (USD Million)
Figure 86. North America Sales Tumor Necrosis Factor Inhibitors Drug Market Forecast (2021-2025) (K Pcs)
Figure 87. Europe Sales Tumor Necrosis Factor Inhibitors Drug Market Forecast (2021-2025) (K Pcs)
Figure 88. Asia-Pacific Sales Tumor Necrosis Factor Inhibitors Drug Market Forecast (2021-2025) (K Pcs)
Figure 89. South America Sales Tumor Necrosis Factor Inhibitors Drug Market Forecast (2021-2025) (K Pcs)
Figure 90. Middle East & Africa Sales Tumor Necrosis Factor Inhibitors Drug Market Forecast (2021-2025) (K Pcs)
Figure 91. Sales Channel: Direct Channel vs Indirect Channel
腫瘍壊死因子受容体スーパーファミリーメンバー9の世界市場 2020年 Market Overview The global Tumor Necrosis Factor Receptor Superfamily Member 9 market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 201…- 消化管間質腫瘍（GIST）治療薬の世界市場 2020年 Market Overview The global Gastrointestinal Stromal Tumor (GIST) Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Ga…
- チロシンキナーゼ阻害剤の世界市場 2020年 Market Overview The global Tyrosine Kinase Inhibitors market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Tyrosine Kinase In…
- ヒト凝固因子VIIの世界市場 2020年 Market Overview The Human Coagulation Factor VII market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimi…
- NT 3成長因子受容体の世界市場 2020年 Market Overview The global NT 3 Growth Factor Receptor market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The NT 3 Growth Facto…